NCT06429150Not yet recruitingPhase 1/2
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 14 May 2024
- Start date
- 31 Dec 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Diseases
- Multiple myeloma
- NCT number
- NCT06429150
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 20
- From 31 Dec 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
Other illness
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Any medical conditions that may preclude participation
Other
- Pregnant or lactating women
Who the study is looking for
- Male and female subjects with multiple myeloma or plasmacytoma
- Strictly complete remission (sCR) is a treatment goal
- Expected survival \> 12 weeks
- After prior auto-SCT is eligible regardless of other prior therapies
- Adequate venous access for apheresis, and no other contraindications for leukapheresis
- Voluntary informed consent is given and commitment to continued follow-up
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.